Abliva AB (publ) (NEVPF) Stock Price, News & Analysis

Company Overview

Abliva AB (publ) is a Swedish life science company focused on the discovery and development of innovative treatments for mitochondrial dysfunction, aiming to restore cellular energy production in patients with rare metabolic and neurodegenerative disorders.

The company’s lead clinical asset, KL1333, is a novel mitochondrial modulator designed to enhance cellular respiration and improve metabolic function in primary mitochondrial disease and related indications.

Abliva leverages proprietary metabolic profiling and translational biomarkers within its research platform to support strategic collaborations and licensing partnerships, advancing its mission to address significant unmet medical needs in mitochondrial medicine.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.03
• 52-Week Range: $0.01 to $0.04
• Volume: N/A
• Average Volume: 4,445 shs
• Market Capitalization: $11.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NEVPF Stock Analysis - Frequently Asked Questions

How have NEVPF shares performed this year?

Abliva AB (publ)'s stock was trading at $0.0360 at the start of the year. Since then, NEVPF shares have decreased by 22.2% and is now trading at $0.0280.

How do I buy shares of Abliva AB (publ)?

Shares of NEVPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NEVPF
• CIK: N/A
• Web: www.neurovive.com
• Phone: (646) 275-6220
• Fax: 46-4-688-883-48
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -117.92%
• Return on Assets: -102.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.99
• Quick Ratio: 7.99

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,128.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 403,010,000
• Free Float: N/A
• Market Cap: $11.28 million
• Optionable: Not Optionable
• Beta: -1.18